33389-38-7

Upstream product

• 71-43-2 benzene 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 51660-08-3 4-Chloro-6-oxo-3-phenyl-1,6-dihydropyridazine 
• 74-88-4 methyl iodide 
• 72857-85-3 α,β-dichloro-γ-phenyl-Δ^α,β-crotonolactone 

Downstream Products

• 518050-94-7 N-[2-(1-methyl-6-oxo-3-phenyl-1,6-dihydropyridazin-4-yl)phenyl]pivalamide 
• 1610354-26-1 1-((3S,4R)-4-(3,4-difluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(1-methyl-6-oxo-3-phenyl-1,6-dihydropyridazin-4-yl)urea 
• 1610354-59-0 phenyl 1-methyl-6-oxo-3-phenyl-1,6-dihydropyridazin-4-ylcarbamate 
• 121106-03-4 5-mercapto-2-methyl-6-phenylpyridazine-3(2H)-thione 
• 121106-01-2 5-mercapto-2-methyl-6-phenylpyridazin-3(2H)-one 
• 518050-95-8 5-(2-aminophenyl)-2-methyl-6-phenylpyridazin-3(2H)-one 
• 518050-96-9 5-(2-azidophenyl)-2-methyl-6-phenylpyridazin-3(2H)-one 
• 126337-06-2 5-azido-2-methyl-6-phenylpyridazin-3(2H)-one 
• 126336-94-5 5-amino-2-methyl-6-phenylpyridazin-3(2H)-one 
• 121105-97-3 5-t-butylthio-2-methyl-6-phenylpyridazin-3(2H)-one 
• 126337-09-5 C₂₉H₂₄N₃OP 

Relevant academic research and scientific papers

PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Pyridazine derivatives. XXIV. Efficient N-methylation of diversely substituted 3(2H)-pyridazinones using N,N-dimethylformamide dimethylacetal

A series of diversely substituted 3(2H)-pyridazinones were efficiently N-methylated at position 2 by treatment with N,N-dimethylformamide dimethylacetal in DMF.

Pyridazines. XV. Synthesis of 6-aryl-5-amino-3(2H)-pyridazinones as potential platelet aggregation inhibitors

Several 3(2H)-pyridazinones with amino groups at the 5-position of the pyridazine nucleus have been prepared. The 6-aryl-5-halo-3(2H)-pyridazinones obtained from mucochloric and mucobromic acid lead to the corresponding 5- alkylamino-3(2H)-pyridazinones,